Second-line treatment of ovarian carcinoma with pegylated liposomal doxorubicin (Caelyx®)
Year: 2008
Session type: Poster / e-Poster / Silent Theatre session
Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK
Abstract
Background
Over 80% of patients with advanced ovarian carcinoma achieve responses to initial platinum- and paclitaxel-based treatment but will ultimately relapse and develop drug-resistant disease. Patients with progression on or within 6 months of primary therapy are considered paltinum-resistant while those who progress within 6 to 12 months are termed potentially platinum-sensitive. Both groups may be treated with Pegylated Liposomal Doxorubicin (Caelyx®) as second line chemotherapy but response rates and survival are poor. We sought to determine the efficacy of Caelyx® for these patient populations in our practice.
Method
Patients with relapsed ovarian carcinoma received Pegylated Liposomal Doxorubicin (Caelyx®) 50mg/m2 every 28 days and were stratified as either platinum-resistant or potentially platinum-sensitive. In this retrospective analysis response rates, progression-free and overall survival for our patient populations were compared with published data.
Results
A total of 52 patients were treated between 2003-2007 of which 39 were platinum-resistant and 13 potentially platinum-sensitive. The median age was 60 (range 37-74). The overall response rate was 7.7% compared to the published rate of 19.7% and for the resistant patients 7.4% compared with 12.3%. Median overall survival times for all and platinum-resistant patients were 31 and 29 weeks respectively, compared with 60 and 35.6 weeks. Progression-free survival for all and platinum-resistant patients were 11.3 and 10.9 respectively compared with 16.1 and 9.1 weeks.
Conclusion
Second-line treatment of platinum-resistant and potentially platinum-sensitive patients with Pegylated Liposomal Doxorubicin (Caelyx®) results in poor response rates and overall survival. Prognosis remains poor in this particularly challenging group of patients.
Background
Over 80% of patients with advanced ovarian carcinoma achieve responses to initial platinum- and paclitaxel-based treatment but will ultimately relapse and develop drug-resistant disease. Patients with progression on or within 6 months of primary therapy are considered paltinum-resistant while those who progress within 6 to 12 months are termed potentially platinum-sensitive. Both groups may be treated with Pegylated Liposomal Doxorubicin (Caelyx®) as second line chemotherapy but response rates and survival are poor. We sought to determine the efficacy of Caelyx® for these patient populations in our practice.
Method
Patients with relapsed ovarian carcinoma received Pegylated Liposomal Doxorubicin (Caelyx®) 50mg/m2 every 28 days and were stratified as either platinum-resistant or potentially platinum-sensitive. In this retrospective analysis response rates, progression-free and overall survival for our patient populations were compared with published data.
Results
A total of 52 patients were treated between 2003-2007 of which 39 were platinum-resistant and 13 potentially platinum-sensitive. The median age was 60 (range 37-74). The overall response rate was 7.7% compared to the published rate of 19.7% and for the resistant patients 7.4% compared with 12.3%. Median overall survival times for all and platinum-resistant patients were 31 and 29 weeks respectively, compared with 60 and 35.6 weeks. Progression-free survival for all and platinum-resistant patients were 11.3 and 10.9 respectively compared with 16.1 and 9.1 weeks.
Conclusion
Second-line treatment of platinum-resistant and potentially platinum-sensitive patients with Pegylated Liposomal Doxorubicin (Caelyx®) results in poor response rates and overall survival. Prognosis remains poor in this particularly challenging group of patients.
